ENDRA Life Sciences (NDRA) Gains from Investment Securities (2024 - 2026)

ENDRA Life Sciences (NDRA) has reported Gains from Investment Securities for 3 consecutive years, with $66702.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gains from Investment Securities rose 207.39% year-over-year to $66702.0 in Q2 2026; TTM through Jun 2026 was $226696.0, a 105.79% increase from a year earlier, with the FY2025 full-year figure at -$319537.0, up 90.73% from the prior year.
• Gains from Investment Securities was $66702.0 for Q2 2026 at ENDRA Life Sciences, up from $8857.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $267274.0 in Q3 2025 and troughed at -$3.3 million in Q3 2024.
• A 3-year average of -$461464.4 and a median of -$84010.0 in 2024 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities decreased 9.66% in 2025 and surged 207.39% in 2026, its largest moves.
• Over 3 years, Gains from Investment Securities stood at -$105908.0 in 2024, then declined by 9.66% to -$116137.0 in 2025, then surged by 157.43% to $66702.0 in 2026.
• The last three Gains from Investment Securities figures came in at $66702.0 (Q2 2026), $8857.0 (Q1 2026), and -$116137.0 (Q4 2025), per Business Quant data.